Abstract
As a promising area of tumor treatment, immunotherapies, such as immune checkpoint inhibitors, have been applied to various types of cancer. However, many patients do not respond to such therapies. Increasing application of tumor ablation therapy, a minimally invasive treatment, has been observed in the clinic. Although it can boost the anti-tumor immune response of patients in many ways, ablation alone is not sufficient to remove the tumor completely or stop tumor recurrence in the long term. Currently, there is emerging research focusing on ablation in combination with immunotherapy, aiming to confirm the therapeutic value of this treatment for cancer patients. Hence, in this article, we review the classification, guideline recommendations, and immunomodulatory effects of ablation therapy, as well as the pre-clinical and clinical research of this combination therapy.
Keywords:
Immune checkpoint inhibitors; Immunotherapy; Oncolytic virus; Thermal ablation; Tumor ablation therapy.
Copyright © 2020 Elsevier B.V. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Ablation Techniques / methods*
-
Ablation Techniques / standards
-
Animals
-
Antineoplastic Agents, Immunological / pharmacology
-
Antineoplastic Agents, Immunological / therapeutic use*
-
B7-H1 Antigen / antagonists & inhibitors
-
B7-H1 Antigen / immunology
-
CTLA-4 Antigen / antagonists & inhibitors
-
CTLA-4 Antigen / immunology
-
Clinical Trials as Topic
-
Combined Modality Therapy / methods
-
Combined Modality Therapy / standards
-
Disease Models, Animal
-
Humans
-
Hyperthermia, Induced / methods*
-
Hyperthermia, Induced / standards
-
Neoplasms / immunology
-
Neoplasms / therapy*
-
Oncolytic Virotherapy / methods*
-
Oncolytic Virotherapy / standards
-
Oncolytic Viruses / immunology
-
Practice Guidelines as Topic
-
Programmed Cell Death 1 Receptor / antagonists & inhibitors
-
Programmed Cell Death 1 Receptor / immunology
-
Treatment Outcome
Substances
-
Antineoplastic Agents, Immunological
-
B7-H1 Antigen
-
CD274 protein, human
-
CTLA-4 Antigen
-
CTLA4 protein, human
-
PDCD1 protein, human
-
Programmed Cell Death 1 Receptor